INSIGHTS ON CLINICAL TRIAL DESIGN
-
Bringing Clinical Trials To Everyone's Backyard
Learn how bringing clinical trials to any community around the world is not only possible but also increases patient access and reach and improves recruitment and retention.
-
Increasing Participation In World-Class Cancer Research In Northwest Arkansas
Discover how data automation and integrated screening help community cancer centers offer clinical research as a standard care option, ensuring all patients have access to the latest treatments.
-
Why Clinical Trial Demographics Don't Match Real-World Populations
Representative trial demographics reduce bias, strengthen safety insights, and ensure therapies work for all. Learn why diversity is essential for accurate data and better health outcomes.
-
ICH E6(R3) Annex 2: Navigating GCP Requirements For Decentralized Trials
Implementing decentralized components or real-world data requires proactive alignment with updated GCP standards for data access, remote consent, and multi-stream investigator oversight.
-
The Psychedelic Setback: What MDMA Rejection Taught Drug Developers6/25/2026
Psychedelic compounds show real promise for PTSD, but proving it requires solving unblinding, bias, and safety gaps in trial design.
-
Shifting Policies Can Spark Progress In Clinical Trial Diversity2/13/2025
Learn how shifting policies create opportunities for the private sector to prioritize innovation in clinical trials for better healthcare.
-
Flexible By Design: Support For Early-Phase Oncology Trial7/8/2026
Shifting cohorts, doses, and protocols challenge early-phase oncology trials. Learn how adaptable technology keeps studies on track.
-
Leveraging Biomarkers In Early PK/PD Studies7/9/2025
Integrating biomarkers into early clinical studies is crucial to determine whether a new therapy engages its biological target, triggers the intended PD effects, and shows early signs of efficacy.
-
How AI Can Accelerate Clinical Trial And Registry Builds6/29/2026
AI tools speed study design — from protocol creation to validation and analysis — by automating complex tasks and generating intelligent data while preserving control, accuracy, and flexibility.
CLINICAL TRIAL DESIGN SOLUTIONS
-
With over 60 HAP studies successfully conducted in the last decade, Altasciences has experience in diverse areas such as for stimulants, opioids, and sedative-hypnotics.
-
Explore an expertly crafted package of programs, products, and expertise addressing the unique challenges of vaccine research.
-
Explore how a multi-omics strategy integrates genomics, transcriptomics, proteomics, spatialomics & pathomics to provide the deep biological insights needed to accelerate precision medicine and clinical development.
-
With over 40 clinical trials conducted in the area of ophthalmology, Altasciences combines depth of knowledge and expert capabilities to offer you a full range of early ophthalmic clinical development.
-
Proof-of-concept provides a critical bridge between Phase 1 and Phase 2 trials, making an experienced CRO partner vital to achieving optimal outcomes for early-phase clinical research.